Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Singer

Showing results (481-490 of 649) with videos related to

Pageof 65
Sort By:
JAMA Oncology|May 1, 2018
Hormone Replacement Therapy After Oophorectomy and Breast Cancer Risk Among BRCA1 Mutation CarriersJoanne Kotsopoulos, Jacek Gronwald, Beth Y Karlan, et al.
ESMO Open|August 9, 2021
ESR1, PGR, ERBB2, and MKi67 mRNA expression in postmenopausal women with hormone receptor-positive early breast cancer: results from ABCSG Trial 6M Filipits, M Rudas, C F Singer, et al.
Gynecologic Oncology|May 26, 2018
Age-specific ovarian cancer risks among women with a BRCA1 or BRCA2 mutationJoanne Kotsopoulos, Jacek Gronwald, Beth Karlan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 12, 2021
The OncoMasTR Test Predicts Distant Recurrence in Estrogen Receptor-Positive, HER2-Negative Early-Stage Breast Cancer: A Validation Study in ABCSG Trial 8Martin Filipits, Margaretha Rudas, Verena Kainz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 22, 2007
Pathologic complete response with six compared with three cycles of neoadjuvant epirubicin plus docetaxel and granulocyte colony-stimulating factor in operable breast cancer: results of ABCSG-14Günther G Steger, Arik Galid, Michael Gnant, et al.
Gynecologic Oncology|April 9, 2013
The incidence of endometrial cancer in women with BRCA1 and BRCA2 mutations: an international prospective cohort studyYakir Segev, Javaid Iqbal, Jan Lubinski, et al.
Annals of Surgical Oncology|June 7, 2013
International rates of breast reconstruction after prophylactic mastectomy in BRCA1 and BRCA2 mutation carriersJohn Semple, Kelly A Metcalfe, Henry T Lynch, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 5, 2012
EndoPredict improves the prognostic classification derived from common clinical guidelines in ER-positive, HER2-negative early breast cancerP Dubsky, M Filipits, R Jakesz, et al.
Gynecologic Oncology|January 22, 2022
Contraceptive use and the risk of ovarian cancer among women with a BRCA1 or BRCA2 mutationYue Yin Xia, Jacek Gronwald, Beth Karlan, et al.
The Lancet. Oncology|February 24, 2019
Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSG-18): disease-free survival results from a randomised, double-blind, placebo-controlled, phase 3 trialMichael Gnant, Georg Pfeiler, Günther G Steger, et al.
Pageof 65

Showing results (481-490 of 649) with videos related to

Sort By:
Pageof 65
JAMA Oncology|May 1, 2018
Hormone Replacement Therapy After Oophorectomy and Breast Cancer Risk Among BRCA1 Mutation CarriersJoanne Kotsopoulos, Jacek Gronwald, Beth Y Karlan, et al.
ESMO Open|August 9, 2021
ESR1, PGR, ERBB2, and MKi67 mRNA expression in postmenopausal women with hormone receptor-positive early breast cancer: results from ABCSG Trial 6M Filipits, M Rudas, C F Singer, et al.
Gynecologic Oncology|May 26, 2018
Age-specific ovarian cancer risks among women with a BRCA1 or BRCA2 mutationJoanne Kotsopoulos, Jacek Gronwald, Beth Karlan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 12, 2021
The OncoMasTR Test Predicts Distant Recurrence in Estrogen Receptor-Positive, HER2-Negative Early-Stage Breast Cancer: A Validation Study in ABCSG Trial 8Martin Filipits, Margaretha Rudas, Verena Kainz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 22, 2007
Pathologic complete response with six compared with three cycles of neoadjuvant epirubicin plus docetaxel and granulocyte colony-stimulating factor in operable breast cancer: results of ABCSG-14Günther G Steger, Arik Galid, Michael Gnant, et al.
Gynecologic Oncology|April 9, 2013
The incidence of endometrial cancer in women with BRCA1 and BRCA2 mutations: an international prospective cohort studyYakir Segev, Javaid Iqbal, Jan Lubinski, et al.
Annals of Surgical Oncology|June 7, 2013
International rates of breast reconstruction after prophylactic mastectomy in BRCA1 and BRCA2 mutation carriersJohn Semple, Kelly A Metcalfe, Henry T Lynch, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 5, 2012
EndoPredict improves the prognostic classification derived from common clinical guidelines in ER-positive, HER2-negative early breast cancerP Dubsky, M Filipits, R Jakesz, et al.
Gynecologic Oncology|January 22, 2022
Contraceptive use and the risk of ovarian cancer among women with a BRCA1 or BRCA2 mutationYue Yin Xia, Jacek Gronwald, Beth Karlan, et al.
The Lancet. Oncology|February 24, 2019
Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSG-18): disease-free survival results from a randomised, double-blind, placebo-controlled, phase 3 trialMichael Gnant, Georg Pfeiler, Günther G Steger, et al.
Pageof 65